Apr 30, 2020
China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Apr 26, 2020
Halozyme Announces Janssen Submits New Drug Application In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's ENHANZE® Technology For Patients With Multiple Myeloma
Apr 24, 2020
Patients Booking COVID-19 Antibody Testing, Euroimmun, Available At Clear Wellness Group, One Of Chicago's Few Clinics Offering The FDA Approved Testing
Apr 22, 2020
FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments
Mar 31, 2020
Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy
Mar 26, 2020
Oncopeptides Announces 26% Overall Response Rate of Melflufen in Triple-class Refractory Multiple Myeloma Patients From the Pivotal HORIZON Study
Mar 26, 2020
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia
Mar 25, 2020
Juntendo University Research: A New Combination Therapy is Effective in Treating a Rare Blood Cancer Cell Type
Mar 20, 2020
Oncopeptides Provides Update Regarding COVID-19 Impact on the Melflufen Clinical Program
Mar 19, 2020
Positive Results from Registrational Study of LENVIMA® (lenvatinib) and KEYTRUDA® (pembrolizumab) in Advanced Endometrial Carcinoma Published in the Journal of Clinical Oncology
Mar 06, 2020
Novadoz Pharmaceuticals Increases Presence in the Generic Oncology Market with an FDA Approval of Thiotepa 15mg &100mg Vials for Injection
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Mar 02, 2020
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
Feb 26, 2020
Actinium Announces Actimab-A Plus 7+3 Combination Trial for Newly Diagnosed Acute Myeloid Leukemia Patients
Feb 15, 2020
Eisai Announces Latest Data for LENVIMA® (lenvatinib) in Combination with Everolimus for Advanced Non-Clear Cell Renal Cell Carcinoma
Feb 10, 2020
Eisai to Present Latest on LENVIMA® (lenvatinib) at the 2020 Genitourinary Cancers Symposium